Education
About Us
Working with TipRanks
Follow Us
CANbridge Pharmaceuticals Inc. (HK:1228)
:1228
1228 Stock Chart & Stats
HK$2.19
<HK$0.01(5.93%)
At close: 4:00 PM EST
HK$2.19
<HK$0.01(5.93%)
Day’s Range― - ―
52-Week RangeHK$0.10 - HK$3.10
Previous CloseN/A
Volume661.00K
Average Volume (3M)5.03M
Market Cap
HK$1.12B
Enterprise ValueHK$159.36M
Total Cash (Recent Filing)HK$1.96M
Total Debt (Recent Filing)HK$34.97M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding510,826,480
10 Day Avg. Volume2,153,700
30 Day Avg. Volume5,027,972
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)0.62
P/FCF Ratio-0.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CANbridge Pharmaceuticals Inc. News
1228 FAQ
What was CANbridge Pharmaceuticals Inc.’s price range in the past 12 months?
CANbridge Pharmaceuticals Inc. lowest stock price was HK$0.10 and its highest was HK$3.10 in the past 12 months.
What is CANbridge Pharmaceuticals Inc.’s market cap?
CANbridge Pharmaceuticals Inc.’s market cap is HK$1.12B.
When is CANbridge Pharmaceuticals Inc.’s upcoming earnings report date?
CANbridge Pharmaceuticals Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 101 days.
How were CANbridge Pharmaceuticals Inc.’s earnings last quarter?
CANbridge Pharmaceuticals Inc. released its earnings results on Aug 31, 2025. The company reported HK$0.154 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.154.
Is CANbridge Pharmaceuticals Inc. overvalued?
According to Wall Street analysts CANbridge Pharmaceuticals Inc.’s price is currently Overvalued.
Does CANbridge Pharmaceuticals Inc. pay dividends?
CANbridge Pharmaceuticals Inc. does not currently pay dividends.
What is CANbridge Pharmaceuticals Inc.’s EPS estimate?
CANbridge Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CANbridge Pharmaceuticals Inc. have?
CANbridge Pharmaceuticals Inc. has 510,826,480 shares outstanding.
What happened to CANbridge Pharmaceuticals Inc.’s price movement after its last earnings report?
CANbridge Pharmaceuticals Inc. reported an EPS of HK$0.154 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of CANbridge Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in HK:1228
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CANbridge Pharmaceuticals Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
696.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-56.79%
Trailing 12-Months
Company Description
CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare diseases and cancers. Headquartered in Beijing, China, the company operates primarily in the biotechnology sector, with a portfolio that includes proprietary drug candidates and strategic partnerships aimed at addressing unmet medical needs in various therapeutic areas, particularly in oncology and rare genetic disorders.
Technical Analysis
Kintor Pharmaceutical Ltd
―
JW (Cayman) Therapeutics Co. Ltd.
―
Clover Biopharmaceuticals Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―